S&P 500   5,059.05 (+1.55%)
DOW   38,888.97 (+0.72%)
QQQ   434.77 (+2.15%)
AAPL   183.27 (+0.52%)
MSFT   410.19 (+1.99%)
META   481.69 (+2.92%)
GOOGL   144.07 (+1.07%)
AMZN   172.12 (+2.09%)
TSLA   194.02 (-0.39%)
NVDA   770.29 (+14.16%)
NIO   5.84 (-2.18%)
AMD   176.37 (+7.35%)
BABA   75.14 (-0.58%)
T   16.67 (-1.94%)
F   12.22 (+0.66%)
MU   84.65 (+3.88%)
CGC   3.43 (-0.29%)
GE   151.26 (+1.47%)
DIS   108.25 (+0.54%)
AMC   4.64 (+1.53%)
PFE   27.30 (-1.34%)
PYPL   57.96 (+0.84%)
XOM   104.40 (-0.43%)
S&P 500   5,059.05 (+1.55%)
DOW   38,888.97 (+0.72%)
QQQ   434.77 (+2.15%)
AAPL   183.27 (+0.52%)
MSFT   410.19 (+1.99%)
META   481.69 (+2.92%)
GOOGL   144.07 (+1.07%)
AMZN   172.12 (+2.09%)
TSLA   194.02 (-0.39%)
NVDA   770.29 (+14.16%)
NIO   5.84 (-2.18%)
AMD   176.37 (+7.35%)
BABA   75.14 (-0.58%)
T   16.67 (-1.94%)
F   12.22 (+0.66%)
MU   84.65 (+3.88%)
CGC   3.43 (-0.29%)
GE   151.26 (+1.47%)
DIS   108.25 (+0.54%)
AMC   4.64 (+1.53%)
PFE   27.30 (-1.34%)
PYPL   57.96 (+0.84%)
XOM   104.40 (-0.43%)
S&P 500   5,059.05 (+1.55%)
DOW   38,888.97 (+0.72%)
QQQ   434.77 (+2.15%)
AAPL   183.27 (+0.52%)
MSFT   410.19 (+1.99%)
META   481.69 (+2.92%)
GOOGL   144.07 (+1.07%)
AMZN   172.12 (+2.09%)
TSLA   194.02 (-0.39%)
NVDA   770.29 (+14.16%)
NIO   5.84 (-2.18%)
AMD   176.37 (+7.35%)
BABA   75.14 (-0.58%)
T   16.67 (-1.94%)
F   12.22 (+0.66%)
MU   84.65 (+3.88%)
CGC   3.43 (-0.29%)
GE   151.26 (+1.47%)
DIS   108.25 (+0.54%)
AMC   4.64 (+1.53%)
PFE   27.30 (-1.34%)
PYPL   57.96 (+0.84%)
XOM   104.40 (-0.43%)
S&P 500   5,059.05 (+1.55%)
DOW   38,888.97 (+0.72%)
QQQ   434.77 (+2.15%)
AAPL   183.27 (+0.52%)
MSFT   410.19 (+1.99%)
META   481.69 (+2.92%)
GOOGL   144.07 (+1.07%)
AMZN   172.12 (+2.09%)
TSLA   194.02 (-0.39%)
NVDA   770.29 (+14.16%)
NIO   5.84 (-2.18%)
AMD   176.37 (+7.35%)
BABA   75.14 (-0.58%)
T   16.67 (-1.94%)
F   12.22 (+0.66%)
MU   84.65 (+3.88%)
CGC   3.43 (-0.29%)
GE   151.26 (+1.47%)
DIS   108.25 (+0.54%)
AMC   4.64 (+1.53%)
PFE   27.30 (-1.34%)
PYPL   57.96 (+0.84%)
XOM   104.40 (-0.43%)
NASDAQ:NAUT

Nautilus Biotechnology (NAUT) Stock Price, News & Analysis

$2.73
-0.04 (-1.44%)
(As of 10:02 AM ET)
Today's Range
$2.73
$2.95
50-Day Range
$2.61
$3.39
52-Week Range
$1.78
$4.65
Volume
3,950 shs
Average Volume
74,672 shs
Market Capitalization
$341.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Nautilus Biotechnology MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
116.6% Upside
$6.00 Price Target
Short Interest
Bearish
2.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.59) to ($0.73) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.34 out of 5 stars

Medical Sector

747th out of 932 stocks

Analytical Instruments Industry

20th out of 27 stocks


NAUT stock logo

About Nautilus Biotechnology Stock (NASDAQ:NAUT)

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was incorporated in 2016 and is headquartered in Seattle, Washington.

NAUT Stock Price History

NAUT Stock News Headlines

Stock To Watch In 2024
Don't wait. Discover this company's major updates happening now.
Nautilus Biotechnology Inc Ordinary Shares
Stock To Watch In 2024
Don't wait. Discover this company's major updates happening now.
Nautilus Biotechnology Inc.
See More Headlines
Receive NAUT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2021
Today
2/22/2024
Next Earnings (Confirmed)
2/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:NAUT
Fax
N/A
Employees
160
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+116.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-57,920,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.53 per share

Miscellaneous

Free Float
71,844,000
Market Cap
$346.11 million
Optionable
Optionable
Beta
1.20
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives















NAUT Stock Analysis - Frequently Asked Questions

Should I buy or sell Nautilus Biotechnology stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nautilus Biotechnology in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" NAUT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NAUT, but not buy additional shares or sell existing shares.
View NAUT analyst ratings
or view top-rated stocks.

What is Nautilus Biotechnology's stock price target for 2024?

1 equities research analysts have issued 1 year price objectives for Nautilus Biotechnology's stock. Their NAUT share price targets range from $6.00 to $6.00. On average, they anticipate the company's share price to reach $6.00 in the next year. This suggests a possible upside of 116.6% from the stock's current price.
View analysts price targets for NAUT
or view top-rated stocks among Wall Street analysts.

How have NAUT shares performed in 2024?

Nautilus Biotechnology's stock was trading at $2.99 at the beginning of the year. Since then, NAUT shares have decreased by 7.4% and is now trading at $2.77.
View the best growth stocks for 2024 here
.

When is Nautilus Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our NAUT earnings forecast
.

How can I listen to Nautilus Biotechnology's earnings call?

Nautilus Biotechnology will be holding an earnings conference call on Wednesday, February 28th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Nautilus Biotechnology's earnings last quarter?

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) announced its quarterly earnings data on Monday, November, 1st. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.02.

Who are Nautilus Biotechnology's major shareholders?

Nautilus Biotechnology's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.26%), Dimensional Fund Advisors LP (0.32%), Nuveen Asset Management LLC (0.15%), Charles Schwab Investment Management Inc. (0.11%), Barclays PLC (0.09%) and Goldman Sachs Group Inc. (0.05%). Insiders that own company stock include Anna Mowry, Gwen E Weld, Life Sciences Maste Perceptive, Matthew B Murphy, Matthew L Posard, Matthew S Mcilwain, Perceptive Advisors Llc, Subramanian Sankar and Sujal M Patel.
View institutional ownership trends
.

How do I buy shares of Nautilus Biotechnology?

Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NAUT) was last updated on 2/22/2024 by MarketBeat.com Staff